CompanyANLNasdaqSingapore

Adlai Nortye Group Ltd.

Adlai Nortye develops cancer therapies including the oral pan-RAS inhibitor AN9025, the CEACAM5-targeting antibody-drug conjugate AN4035, and AN8025, a PD-1/L1 pathway fusion protein.

Stories only

SEC EDGAR ClinicalTrials.gov ir.adlainortye.com

6-KSep 30Latest SEC filing

Sep 30Latest story

September 2026

Adlai Nortye names Christopher Liu head of investor and public relations

Sep 30PeopleAdlai Nortye Group Ltd.

August 2026

Adlai Nortye clears Australian regulatory steps for AN4035 phase I trial

Aug 3Regulatory decisionAdlai Nortye Group Ltd.

July 2026

Adlai Nortye doses first patient in weekly-dosing arm of AN9025 Phase 1 trial

Jul 16Clinical readoutAdlai Nortye Group Ltd.